$5.7 MILLION NET RAISED FOR CANCER CARE IN ATLANTIC CANADA SINCE 2015
Atlantic Canada’s first surgical robotics technology at the QEII
Atlantic Canada’s first surgical robotics technology for prostate, kidney, gynecological and ear, nose and throat (ENT) cancer surgeries at the QEII. Thanks to our BMO Ride community and QEII Foundation donors, robot-assisted surgery is now a treatment option for certain cancer patients. Healing is faster. Hospital stays are shorter. Normal life resumes sooner. More than 500 robotic cancer surgeries have been performed to date at the QEII. View a virtual tour of the surgical robot here.
Pictured: Members of the QEII’s urology team, Dr. Ross Mason (left) and Dr. Ricardo Rendon, who use the surgical robot to perform prostate and kidney cancer surgeries for their patients.
New state-of-the-art colposcope for the QEII’s colposcopy clinic
New state-of-the-art colposcope equipment for the QEII’s colposcopy clinic. This minimally-invasive tool helps diagnose and prevent cervical cancer by detecting and treating precancerous cells. With up to 200 Atlantic Canadian patients visiting the clinic each week, the impact of this diagnostic equipment is beyond measure – in some cases, unlocking the ability to stop cervical cancer in its tracks.
Pictured: Members of the QEII’s colposcopy clinic with one of four colposcopes funded by our BMO Ride community.
QEII’s new Cancer Therapy Preparation Lab
Technology and equipment within the QEII’s new Cancer Therapy Preparation Lab, which is set to fully open in 2022. This state-of-the-art lab will be dedicated to the preparation of all drugs for the treatment and support of cancer patients at the QEII. With our BMO Ride community helping to fund innovative technologies within the new lab – like bar-coding, remote-cameras and automation – the QEII’s cancer care team will double the number of therapy doses they can prepare each day, reduce treatment times, and enable new clinical trials.
Pictured: Technician, Meghan Davis, stands in front of a BMO Ride-funded biological safety cabinet in the QEII’s new Cancer Therapy Preparation Lab. This cabinet is where critical doses, like chemotherapy, are safely prepared before they’re delivered to QEII patients awaiting systemic therapy treatments
Cutting-edge genetic sequencing technology at the QEII
Cutting-edge genetic sequencing technology at the QEII. In 2022, the QEII will become home to a best-in-class genetic sequencing machine, which will analyze the genes of thousands of tumour samples each year. This data can inform care teams how a patient’s cancer might progress and the most effective treatment options. Fewer side effects, better outcomes, more clinical trial opportunities, and, in some, cases sparing patients from unnecessary treatments. These are all benefits our BMO Ride community will soon make possible.
Pictured: An example of a genetic sequencing machine, much like the one the QEII will soon become home to.
The QEII’s first endobronchial ultrasound (EBUS) technology
The QEII’s first endobronchial ultrasound (EBUS) technology, which provides a safer and less-invasive option for diagnosing lung cancer and lymphoma. Before our BMO Ride community stepped up, Nova Scotia was the only province in Canada that didn’t have EBUS technology. Better diagnoses, reduced risk for patients, less pain, faster recovery times and an extra 100 diagnostic procedures performed each year are all benefits our BMO Ride community helped make possible.
Pictured: QEII respirologist, Dr. Simon Houston, pictured with the EBUS technology funded by our BMO Ride community
Additional apheresis machine for the QEII’s Medical Day Unit
Additional apheresis machine for the QEII’s Medical Day Unit. An apheresis machine separates blood components to treat certain blood cancer patients, and also plays a critical role in stem cell transplants; enabling an additional three transplants to occur each week at the QEII thanks to the increased capacity.
Pictured: A patient undergoes apheresis treatment within the QEII’s Medical Day Unit, thanks to the help of our BMO Ride community.
Chemotherapy pumps, chairs & portable monitoring equipment within the QEII’s Medical Day Unit
Chemotherapy pumps, chemotherapy chairs and portable monitoring equipment within the QEII’s Medical Day Unit. Operating seven days a week, the QEII’s Medical Day Unit is one of the busiest outpatient clinics at the QEII as the primary treatment area for blood cancer patients receiving chemotherapy and supportive care. Our BMO Ride community funded these vital care items, improving the treatment experience and overall comfort for cancer patients.
Pictured: A patient receives cancer treatment within the QEII’s Medical Day Unit
Blood cancer research and patient education and support programs
Blood cancer research and patient education and support programs. Our BMO Ride community supported groundbreaking research to help discover new treatments and cures for blood cancer, as well as individualized support programs for cancer patients and their families through The Leukemia & Lymphoma Society of Canada.